Copy to clipboard 
Smith+Nephew reported 4Q19 orthopedic revenue of USD $1,002.4 million, +7.7% vs. 4Q18, with full-year 2019 revenue of $3,663.3 million, +4.1% vs. 2018. The company built upon improved momentum from 3Q, particularly in sports medicine where an aging portfolio of enabling technology had been a hindrance. The recently launched LENS 4K visualization system, combined with ongoing strong sales of sports medicine joint repair products, drove full-year mid-single-digit growth for Smith+Nephew’s sports medicine business. Like other large players, the company is increasing focus on and investment in digital health. New products like the Journey II knee implant, in addition to enabling technologies like NAVIO and the assets acquired from Brainlab, helped drive above-market knee and hip replacement growth for 4Q. Coverage of total knee replacements in outpatient centers also presents Smith+Nephew with an opportunity to leverage its existing presence and strength in ASCs.
“Reimbursement changes within the ASC opportunity with new coverage of total knee replacement from 2020 onwards will certainly help there and we look to leverage our existing advantages such as our position in sports medicine and CT-free robotics for this specific ASC segment.” – Smith+Nephew CEO Roland Diggelmann
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 4Q19 | 4Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $483.5 | $462.1 | $21.4 | 4.6% |
| Knees | $302.3 | $288.0 | $14.3 | 5% |
| Hips | $166.7 | $160.0 | $6.7 | 4.2% |
| Extremities | $14.5 | $14.1 | $0.4 | 3.1% |
| Trauma | $116.5 | $108.9 | $7.6 | 6.9% |
| Sports Medicine | $384.0 | $350.0 | $34.0 | 9.7% |
| Orthobiologics | $18.4 | $9.9 | $8.6 | 86.9% |
| Total | $1,002.4 | $930.9 | $71.6 | 7.7% |
| FY19 | FY18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,787.9 | $1,744.9 | $43.0 | 2.5% |
| Knees | $1,111.6 | $1,079.0 | $32.6 | 3% |
| Hips | $622.4 | $613.0 | $9.4 | 1.5% |
| Extremities | $53.9 | $52.9 | $1.0 | 1.9% |
| Trauma | $434.1 | $423.1 | $11.0 | 2.6% |
| Sports Medicine | $1,385.0 | $1,316.0 | $69.0 | 5.2% |
| Orthobiologics | $56.3 | $33.7 | $22.6 | 66.9% |
| Total | $3,663.3 | $3,517.7 | $145.6 | 4.1% |
Geographic Sales
| Geographic Region | 4Q19 | 4Q18 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $515.8 | $466.9 | $49.0 | 10.5% |
| Ex-US | $486.6 | $464.0 | $22.6 | 4.9% |
| EMEA | $261.0 | $261.1 | ($0.1) | (0%) |
| Asia Pacific | $120.5 | $109.1 | $11.3 | 10.4% |
| Rest of World | $105.1 | $93.8 | $11.4 | 12.1% |
| Total | $1,002.4 | $930.9 | $71.6 | 7.7% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Smith+Nephew reported 4Q19 orthopedic revenue of USD $1,002.4 million, +7.7% vs. 4Q18, with full-year 2019 revenue of $3,663.3 million, +4.1% vs. 2018. The company built upon improved momentum from 3Q, particularly in sports medicine where an aging portfolio of enabling technology had been a hindrance. The recently launched LENS 4K...
Smith+Nephew reported 4Q19 orthopedic revenue of USD $1,002.4 million, +7.7% vs. 4Q18, with full-year 2019 revenue of $3,663.3 million, +4.1% vs. 2018. The company built upon improved momentum from 3Q, particularly in sports medicine where an aging portfolio of enabling technology had been a hindrance. The recently launched LENS 4K visualization system, combined with ongoing strong sales of sports medicine joint repair products, drove full-year mid-single-digit growth for Smith+Nephew’s sports medicine business. Like other large players, the company is increasing focus on and investment in digital health. New products like the Journey II knee implant, in addition to enabling technologies like NAVIO and the assets acquired from Brainlab, helped drive above-market knee and hip replacement growth for 4Q. Coverage of total knee replacements in outpatient centers also presents Smith+Nephew with an opportunity to leverage its existing presence and strength in ASCs.
“Reimbursement changes within the ASC opportunity with new coverage of total knee replacement from 2020 onwards will certainly help there and we look to leverage our existing advantages such as our position in sports medicine and CT-free robotics for this specific ASC segment.” – Smith+Nephew CEO Roland Diggelmann
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 4Q19 | 4Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $483.5 | $462.1 | $21.4 | 4.6% |
| Knees | $302.3 | $288.0 | $14.3 | 5% |
| Hips | $166.7 | $160.0 | $6.7 | 4.2% |
| Extremities | $14.5 | $14.1 | $0.4 | 3.1% |
| Trauma | $116.5 | $108.9 | $7.6 | 6.9% |
| Sports Medicine | $384.0 | $350.0 | $34.0 | 9.7% |
| Orthobiologics | $18.4 | $9.9 | $8.6 | 86.9% |
| Total | $1,002.4 | $930.9 | $71.6 | 7.7% |
| FY19 | FY18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,787.9 | $1,744.9 | $43.0 | 2.5% |
| Knees | $1,111.6 | $1,079.0 | $32.6 | 3% |
| Hips | $622.4 | $613.0 | $9.4 | 1.5% |
| Extremities | $53.9 | $52.9 | $1.0 | 1.9% |
| Trauma | $434.1 | $423.1 | $11.0 | 2.6% |
| Sports Medicine | $1,385.0 | $1,316.0 | $69.0 | 5.2% |
| Orthobiologics | $56.3 | $33.7 | $22.6 | 66.9% |
| Total | $3,663.3 | $3,517.7 | $145.6 | 4.1% |
Geographic Sales
| Geographic Region | 4Q19 | 4Q18 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $515.8 | $466.9 | $49.0 | 10.5% |
| Ex-US | $486.6 | $464.0 | $22.6 | 4.9% |
| EMEA | $261.0 | $261.1 | ($0.1) | (0%) |
| Asia Pacific | $120.5 | $109.1 | $11.3 | 10.4% |
| Rest of World | $105.1 | $93.8 | $11.4 | 12.1% |
| Total | $1,002.4 | $930.9 | $71.6 | 7.7% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
